PL90029B1 - - Google Patents
Download PDFInfo
- Publication number
- PL90029B1 PL90029B1 PL1970173768A PL17376870A PL90029B1 PL 90029 B1 PL90029 B1 PL 90029B1 PL 1970173768 A PL1970173768 A PL 1970173768A PL 17376870 A PL17376870 A PL 17376870A PL 90029 B1 PL90029 B1 PL 90029B1
- Authority
- PL
- Poland
- Prior art keywords
- formula
- group
- carbon atoms
- alkyl
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 150000002825 nitriles Chemical group 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- -1 hydroxy, amino Chemical group 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- MFEDKMBNKNOUPA-UHFFFAOYSA-N (2-bromo-4,7-dimethyl-3-oxo-7-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(C)C(=O)C(Br)C1C2(CS(O)(=O)=O)C MFEDKMBNKNOUPA-UHFFFAOYSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VBKFBHWKPDYMSY-UHFFFAOYSA-N 3-methyl-4-[[3-(1-methylcyclohexyl)-2-oxo-1,3-oxazolidin-5-yl]methoxy]benzonitrile Chemical compound CC1(CCCCC1)N1C(OC(C1)COC1=C(C=C(C=C1)C#N)C)=O VBKFBHWKPDYMSY-UHFFFAOYSA-N 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- FJRYUYOWGGVHLU-UHFFFAOYSA-N C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 Chemical compound C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 FJRYUYOWGGVHLU-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- JNGGZQKHBCIQEF-UHFFFAOYSA-N Cl.CC1=C(OCC(CNC2(CCCCC2)C)O)C=CC(=C1)C#N Chemical compound Cl.CC1=C(OCC(CNC2(CCCCC2)C)O)C=CC(=C1)C#N JNGGZQKHBCIQEF-UHFFFAOYSA-N 0.000 description 1
- NBMLCRXFZDEBLJ-UHFFFAOYSA-N ClC1=C(OC(C(CC2(CCCC2)C)O)N)C=C(C=C1)C Chemical compound ClC1=C(OC(C(CC2(CCCC2)C)O)N)C=C(C=C1)C NBMLCRXFZDEBLJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RXMXLUZCKAYIGA-UHFFFAOYSA-N [N+](=O)([O-])C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 Chemical compound [N+](=O)([O-])C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 RXMXLUZCKAYIGA-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
- E04H13/00—Monuments; Tombs; Burial vaults; Columbaria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Architecture (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Structural Engineering (AREA)
- Civil Engineering (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarzania nowych, racemicznych lub optycznie czynnych, 1-feno- ksy-2-hydroksy-3-cykloalkiloaminopropanów i ich soli addycyjnych z kwasami.Nowym zwiazkom odpowiada wzór 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Rx oznacza grupe nitrylowa (-C^N), karboksylowa, hydroksylowa, aminowa, nitrowa lub trójfluorome- tylowa lub grupe alkilowa, alkenylowa, alkinylowa, alkoksylowa, alkenyloksylowa, alkinyloksylowa, hydroksyal- kilowa, alkoksyalkilowa, aminoalkilowa, alkiloaminoalkilowa,dwualkiloaminoalkilowa, alkiloaminowa, nitryloal- kilowa! alkoksykarbonylowa, alkiloaminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe arylowa, aralkilowa, aryloksylowa, aralkoksylowa lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec, grupe nitrylowa lub grupe alkilowa, alkoksylowa lub alkenylowa, zawierajaca do 5 atomów wegla lub razem z Ht oznacza grupe 3,4-metylenodwuoksylowa, bez dalszych podstawników, R3 oznacza wodór, chlorowiec, grupe alkilowa lub alkoksylowa, zawierajaca do 5 atomów wegla i n oznacza liczbe calkowita 2-7.Nowe zwiazki wedlug wynalazku wytwarza sie przez hydrolize oksazolidynonu o wzorze 2, w którym wszystkie symbole maja wyzej podane znaczenie, np. za pomoca mocnych alkaliów, w wodnym lub wodno-alko- holowym srodowisku.Oksazolidynony o wzorze 2 wytwarza sie, np. z odpowiednich epoksydów, przez reakcje tych ostatnich zuretanem o wzorze 3, w którym R in maja podane znaczenie, utworzonym z estru etylowego kwasu mrówkowego i alkiloaminy.Zwiazki otrzymywane sposobem wedlug wynalazku maja asymetryczny atom wegla w grupie CHOH i wystepuja wskutek tego w postaci racematu i optycznych antypodów. Te ostatnie otrzymuje sie przez rozdzielenie racematu za pomoca zwykle uzywanych kwasów pomocniczych, takich jak kwas dwubenzoilo-D-wi- nowy lub D-3-bromokamforo-8-sulfonowy oraz przez stosowanie optycznie czynnych zwiazków wyjsciowych.Otrzymywane sposobem wedlug wynalazku 1-fenoksy-3-cykloalkiloaminopropanole o wzorze 1 mozna w znany sposób przeprowadzic w ich fizjologicznie dopuszczalne sole addycyjne z kwasami. Odpowiednimi kwasami sa, np. kwas solny, kwas bromowodorowy, kwas siarkowy, kwas metanosulfonowy, kwas maleinowy, kwas octowy, kwas szczawiowy, kwas mlekowy, kwas winowy lub 8-chloroteofilina. ?2 90029 Zwiazki o wzorze 1 wzglednie ich fizjologicznie dopuszczalne sole addycyjne z kwasami wykazaly w badaniach na swinkach morskich jako zwierzetach doswiadczalnych wartosciowe wlasciwosci terapeutyczne, w szczególnosci dzialanie |3-adrenolityczne i mozna je wskutek tego stosowac do leczenia i profilaktyki w scho¬ rzeniach naczyn wiencowych serca i arytmii serca, zwlaszcza tychocardii, w medycynie. Równiez dzialanie obnizajace cisnienie krwi jest pod wzgledem terapeutycznym bardzo interesujace.Wartosciowymi w szczególnosci okazaly sie takie zwiazki o wzorze 1, w którym R oznacza grupe metylowa, R2 i Ra oznaczaja zwlaszcza wodór, a równiez grupe alkilowa i Rt oznacza zwlaszcza nienasycona grupe, taka jak grupa etynylowa, nitrylowa, allilowa lub alliloksylowa (w szczególnosci w polozeniu 2 lancucha propanolowego) lub równiez grupa hydroksymetylowa i n = 4,5 lub 6. Równiez, gdy R oznacza grupe metylowa, Ri oznacza chlorowiec i R2 oznacza wodór wzglednie grupe metylowa i R3 oznacza wodór, a n = 4,5 lub 6, zwiazki takie wykazuja mocne dzialanie j3-adrenolityczne. Szczególnie wartosciowymi pod wzgledem terapeu¬ tycznym sa: 1 -(2-etynylofenoksy)-2-hydroksy-3-(1 -metylocyklopentylo)-aminopropan, równiez 1 -(2-pitrylofenoV ksy)-2-hydroksy-3-(1-metylocyklopentylo) -aminopropan oraz l-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylocy- kloheksylo)-aminopropan, 1-(2-chloro-5-metylofenoksy)-2-hydroksy-3-(1-metylocyklopentylo)-aminopropan, 1-(2-hydroksymetylofenoksy-hydroksy-3-(1 -metylocykloheksylo)-aminopropan i 1-(2-bromofenoksy^-hydro¬ ksyl 1-metylocykloheptylo)-aminopropan oraz ich fizjologicznie dopuszczalne sole addycyjne z kwasami.W szczególnosci interesujacym pod wzgledem terapeutycznym jest 1-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylo- cyklopentylo)-aminopropan wskutek swego antagonistycznego wobec izopreterenolu dzialania, przy prawie calkowitym braku wlasnego dzialania powodujacego rzadkoskurcz.Szczególnie aktywnymi sa równiez zwiazki, w których grupa fenylowa jest podstawiona grupa nitrylowa w polozeniu 2 i równoczesnie nizsza grupa alkilowa, zwlaszcza metylowa w polozeniu 5, np. 1-(2-nitrylo-5-metyr lofenoksy)-2-hydroksy-3-(1 -metylocyklopentyloamino)-propan 1 (2-nitrylo-5-metylofenoksy)-2-hydroksy-3-(1- metylocyklohekSyloamino)-propan i 1-(2-nitrylo-5-metylofenoksy)-2-hydroksy-3-(1-metylocykloheptyloamino)- -propan oraz ich fizjologicznie dopuszczalne sole addycyjne z kwasami.Dawka jednostkowa substancji otrzymywanych sposobem wedlug wynalazku wynosi 1—300 mg, zwlaszcza —100 mg doustnie oraz 1—20 mg pozajelitowe Galenowa obróbke zwiazków otrzymywanych sposobem wedlug wynalazku do zwyklych form uzytko¬ wych, takich jak roztwory, emulsje, tabletki, drazetki lub preparaty o przedluzonym dzialaniu, przeprowadza sie w znany sposób stosujac galenowe srodki pomocnicze, nosniki, srodki rozkruszajace, wiazace, powlokowe lub nadajace poslizg, substancje smakowe, slodzace, srodki powodujace przedluzone dzialanie oraz ulatwiajace rozpuszczanie. Mozna równiez zwiazki otrzymywane sposobem wedlug wynalazku laczyc z innymi substancjami farmakodynamicznymi, takimi jak srodki rozszerzajace naczynia wiencowe, sympatykomimetyczne, glikozydy nasercowe, lub srodki uspokajajace.Nastepujacy przyklad wyjasnia blizej wynalazek, nie ograniczajac jego zakresu.Przyklad. Chlorowodorek 1-(2-metylo-4-cyjanofenoksy)-2-hydroksy-3-(1-metylocykloheksyloamino)- propanu. 1,1 g 3-(1-metylocykloheksylo)-5-(2-metylo-4-cyjanofenoksymetylo)-oksazolidynonu w 20 ml etanolu i 4- ml wody z0,6g KOH ogrzewa sie do wrzenia pod chlodnica zwrotna przez 90 minut. Po oddestylowaniu rozpuszczalnika dodaje sie wode i ekstrahuje eterem. Faze eterowa przemywa sie woda i suszy nad MgS04. Po oddestylowaniu eteru pozostalosc rozpuszcza sie w malej ilosci etanolu, dodaje eterowy roztwór HCI i oddziela wytracony chlorowodorek. Wydajnosc: 0,28 g, temperatura topnienia: 202—206°C.Analogicznie jak w podanym przykladzie wytwarza sie nastepujace zwiazki: * l 2-CN 2-CN 2-Br 2-C1 2-Br 2-CHa=CH 2-CHaCH=CHa 2 H H H - H H H CH3 R3 3 H H H H H H H R 4 CH3 CH3 CH3 CH3 CH3 CH3 CH3 n 4 4 4 Temperatura topnienia (chlorowodorek) 6 163-165 132-134 156-157 170-172 157-158 137-138 141-143 (szczawian)90 029 3 1 2-OCH 2-Br 2-a 2-a 2-CN 2-CH,G=CH 2-CR,CH= 2-C=CH 2-CN 2-C1 2-CN =CH2 2-CH3OCH 2-CH2CH= 2-CHaCH= 2-CH2CH= 2-CH2OH 2-CN 2-NH, 2-CN 2-CN 2-CN =CH2 =CHa =CH3 2 H H - - H H H H H - H H H H H H 4- H CH, CH, CH3 a -CH9 - - CH3 CH3 3 H H H H H H H H H H H H H H H H H H H H H 4 CH3 CH3 CH3 C2H5 C2H5 CH3 CH3 CH3 i-C3H7 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH, CH, CH3 4 6 4 4 6 6 6 6 4 6 4 6 171-173 167-168 174-177 179-180 157-158 167-168 110-111 184-185 200-201 191-194 160-161 110-111 124-126 97- 99 100-101 (szczawian) 211-212 (szczawian) 194-196 235-237 (dwuchlorowodorek) 173-176 192-194 143-146 *. PL PL PL PL PL PL
Claims (4)
1. Zastrzezenie patentowe Sposób wytwarzania nowych 1. -fenoksy-
2. -hydroksy-
3. -cykloalkiloaminopropanów o wzorze 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Ri oznacza grupe nitrylowa, grupe karboksylowa, hydroksylowa, aminowa, nitrowa lub trójfluorcmetylowa albo grupe alkilowa, alkenylowa, alkinylowa, alkoksy- lowa, alkenyloksylowa, alkinyloksylowa, hydroksyalkilowa, alkoksyalkilowa, aminoalkilowa, alkiloaminoalki- lowa, dwualkiloaminoalkilowa, alkiloaminowa, cwualkiloaminowa, nitryloalkilowa, al koksykarbonyIowa, alkilo- aminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe arylowa, aralkilowa, aryloksylowa, aralkoksylowa lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec, grupe nitrylowa lub alkilowa, alkoksyIowa lub alkenylowa, zawierajaca do 5 atomów wegla, R3 oznacza wodór, chlorowiec, grupe alkilowa lub a I koksy Iowa, zawierajaca do 5 atomów wegla lub Rx i R2 razem oznaczaja grupe 3,
4. -metylenodwuoksylowa, w którym to przypadku R3 oznacza wodór i n oznacza liczbe calkowita 2—7, w postaci racematu lub izomerów optycznie czynnych oraz ich fizjologicznie dopuszczalnych soli addycyjnych z kwasami, znamienny tym, ze oksazolidynon o wzorze 2, w którym R, Ri —R3 i n maja wyzej podane znaczenie, poddaje sie hydrolizie i otrzymany zwiazek o wzorze 1, o ile jest w postaci racematu, ewentualnie przeprowadza sie, przez reakcje z odpowiednim kwasem pomocni¬ czym, w diastereometryczne sole, które rozdziela sie na drodze frakcjonowanej krystalizacji na optycznie czynne antypody i zwiazki o wzorze 1 ewentualnie przeprowadza w ich fizjologicznie dopuszczalne sole addycyjne z kwasami.90 029 r; r. 0CH2-CH0H-CH2-NH-CjCH2)n R WZÓR 1 ^7-0CH-CH-CK RT ~r 2 i -i 2 R3 0vN-CjCH2)n I R 0 WZdR 2 (CHj^JC-HN-C-OCjH R O WZdR 3 Prac. Poligraf. UP PRL naklad 120+18 Cena 10 zl PL PL PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1937477A DE1937477C3 (de) | 1969-07-23 | 1969-07-23 | I -Phenoxy-2-hydroxy-3-(l -methylcycloalkylamino)-propane, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL90029B1 true PL90029B1 (pl) | 1976-12-31 |
Family
ID=5740681
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173765A PL90039B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173768A PL90029B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173769A PL90028B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173765A PL90039B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173769A PL90028B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3755413A (pl) |
| JP (5) | JPS5133106B1 (pl) |
| AT (9) | AT304475B (pl) |
| BE (1) | BE753774A (pl) |
| BG (9) | BG17508A3 (pl) |
| CH (10) | CH550139A (pl) |
| CS (9) | CS170528B2 (pl) |
| DE (1) | DE1937477C3 (pl) |
| DK (1) | DK140281B (pl) |
| ES (8) | ES382014A1 (pl) |
| FR (1) | FR2059551B1 (pl) |
| GB (1) | GB1314896A (pl) |
| NL (1) | NL169874C (pl) |
| PL (9) | PL90030B1 (pl) |
| RO (9) | RO60112A (pl) |
| SE (1) | SE370391B (pl) |
| YU (5) | YU34395B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3937706A (en) * | 1969-07-23 | 1976-02-10 | Boehringer Ingelheim Gmbh | 1-(2'ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propanes and salts thereof |
| US4021576A (en) * | 1969-07-23 | 1977-05-03 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing a 1-(2'-ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propane and method of use |
| US4038313A (en) * | 1970-01-08 | 1977-07-26 | Ciba-Geigy Corporation | Cycloalkylureido phenoxy propanolamines |
| US4120978A (en) * | 1970-01-08 | 1978-10-17 | Ciba-Geigy Corporation | Pharmaceutical composition for inhibiting and blocking cardioselective beta-receptors |
| SE354851B (pl) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US4145442A (en) * | 1972-04-04 | 1979-03-20 | Aktiebolaget Hassle | Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases |
| US4038414A (en) * | 1972-06-08 | 1977-07-26 | Ciba-Geigy Corporation | Amines and processes for their manufacture |
| US4035420A (en) * | 1972-07-06 | 1977-07-12 | Aktiebolaget Hassle | Substituted ureido alkylene phenoxy propanolamines |
| DE2309887C2 (de) * | 1973-02-28 | 1983-11-10 | C.H. Boehringer Sohn, 6507 Ingelheim | 1-Aryloxy-2-hydroxy-3-alkinylaminopropan-Derivate und deren physiologisch verträgliche Säureadditionssalze, pharmazeutische Präparate und Herstellungsverfahren für die Verbindungen |
| US4220659A (en) * | 1974-02-22 | 1980-09-02 | Boehringer Ingelheim Gmbh | 1-Phenoxy-2-hydroxy-3-alkynylamino-propanes and salts thereof |
| DK405775A (da) * | 1974-09-12 | 1976-03-13 | American Cyanamid Co | Fremgangsmade til fremstilling af alkanolaminer |
| US4165384A (en) * | 1974-11-01 | 1979-08-21 | Aktiebolaget Hassle | Amide substituted phenoxy propanol amines |
| US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
| US4471127A (en) * | 1981-09-08 | 1984-09-11 | Ciba-Geigy Corporation | 1-5-Bis-(1,4-benzodioxin-2-yl)-3-azapentane-1,5-diols |
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| JPS6364630U (pl) * | 1986-10-17 | 1988-04-28 |
-
1969
- 1969-07-23 DE DE1937477A patent/DE1937477C3/de not_active Expired
-
1970
- 1970-03-22 BG BG017138A patent/BG17508A3/xx unknown
- 1970-03-23 BG BG017134A patent/BG17750A3/xx unknown
- 1970-07-16 CH CH224973A patent/CH550139A/xx not_active IP Right Cessation
- 1970-07-16 CH CH1087370A patent/CH537360A/de not_active IP Right Cessation
- 1970-07-16 CH CH224273A patent/CH536809A/de not_active IP Right Cessation
- 1970-07-16 CH CH1106675A patent/CH575376A5/xx not_active IP Right Cessation
- 1970-07-16 CH CH224673A patent/CH536811A/de not_active IP Right Cessation
- 1970-07-16 CH CH224473A patent/CH550140A/xx not_active IP Right Cessation
- 1970-07-16 CH CH224873A patent/CH536813A/de not_active IP Right Cessation
- 1970-07-16 CH CH224573A patent/CH536810A/de not_active IP Right Cessation
- 1970-07-16 CH CH224373A patent/CH570363A5/xx not_active IP Right Cessation
- 1970-07-16 CH CH224773A patent/CH536812A/de not_active IP Right Cessation
- 1970-07-20 RO RO69799A patent/RO60112A/ro unknown
- 1970-07-20 RO RO69806A patent/RO59211A/ro unknown
- 1970-07-20 RO RO63988A patent/RO56318A/ro unknown
- 1970-07-20 RO RO69803A patent/RO59159A/ro unknown
- 1970-07-20 RO RO69804A patent/RO59209A/ro unknown
- 1970-07-20 RO RO69798A patent/RO60111A/ro unknown
- 1970-07-20 RO RO69805A patent/RO59210A/ro unknown
- 1970-07-20 RO RO69802A patent/RO59089A/ro unknown
- 1970-07-20 RO RO69801A patent/RO59112A/ro unknown
- 1970-07-21 PL PL1970173767A patent/PL90030B1/pl unknown
- 1970-07-21 CS CS4505A patent/CS170528B2/cs unknown
- 1970-07-21 PL PL1970173770A patent/PL90027B1/pl unknown
- 1970-07-21 CS CS4507A patent/CS170530B2/cs unknown
- 1970-07-21 GB GB3535970A patent/GB1314896A/en not_active Expired
- 1970-07-21 PL PL1970173765A patent/PL90039B1/pl unknown
- 1970-07-21 CS CS4506A patent/CS170529B2/cs unknown
- 1970-07-21 PL PL1970173772A patent/PL90025B1/pl unknown
- 1970-07-21 ES ES382014A patent/ES382014A1/es not_active Expired
- 1970-07-21 PL PL1970173768A patent/PL90029B1/pl unknown
- 1970-07-21 CS CS5136A patent/CS170524B2/cs unknown
- 1970-07-21 CS CS4504A patent/CS170527B2/cs unknown
- 1970-07-21 PL PL1970173771A patent/PL90026B1/pl unknown
- 1970-07-21 CS CS4508A patent/CS170531B2/cs unknown
- 1970-07-21 PL PL1970142196A patent/PL79772B1/pl unknown
- 1970-07-21 CS CS4509A patent/CS170532B2/cs unknown
- 1970-07-21 CS CS4502A patent/CS170525B2/cs unknown
- 1970-07-21 PL PL1970173769A patent/PL90028B1/pl unknown
- 1970-07-21 CS CS4503A patent/CS170526B2/cs unknown
- 1970-07-21 PL PL1970173766A patent/PL90038B1/pl unknown
- 1970-07-22 BG BG017136A patent/BG17507A3/xx unknown
- 1970-07-22 BG BG018645A patent/BG19132A3/xx unknown
- 1970-07-22 BE BE753774D patent/BE753774A/xx not_active IP Right Cessation
- 1970-07-22 JP JP45063634A patent/JPS5133106B1/ja active Pending
- 1970-07-22 BG BG015254A patent/BG17749A3/xx unknown
- 1970-07-22 YU YU1860/70A patent/YU34395B/xx unknown
- 1970-07-22 BG BG017137A patent/BG18852A3/xx unknown
- 1970-07-22 US US00057353A patent/US3755413A/en not_active Expired - Lifetime
- 1970-07-22 DK DK380170AA patent/DK140281B/da unknown
- 1970-07-22 BG BG017135A patent/BG17751A3/xx unknown
- 1970-07-23 FR FR7027291A patent/FR2059551B1/fr not_active Expired
- 1970-07-23 AT AT118272A patent/AT304475B/de active
- 1970-07-23 AT AT674870A patent/AT303706B/de not_active IP Right Cessation
- 1970-07-23 SE SE7010200A patent/SE370391B/xx unknown
- 1970-07-23 AT AT118372A patent/AT304476B/de not_active IP Right Cessation
- 1970-07-23 AT AT118172A patent/AT304474B/de active
- 1970-07-23 AT AT117972A patent/AT306702B/de not_active IP Right Cessation
- 1970-07-23 AT AT118672A patent/AT306704B/de not_active IP Right Cessation
- 1970-07-23 AT AT118572A patent/AT304478B/de active
- 1970-07-23 AT AT118472A patent/AT304477B/de not_active IP Right Cessation
- 1970-07-23 AT AT118072A patent/AT306703B/de not_active IP Right Cessation
- 1970-07-23 NL NLAANVRAGE7010928,A patent/NL169874C/xx not_active IP Right Cessation
- 1970-07-24 BG BG017133A patent/BG17506A3/xx unknown
- 1970-07-24 BG BG017132A patent/BG17505A3/xx unknown
-
1971
- 1971-09-09 ES ES394916A patent/ES394916A1/es not_active Expired
- 1971-09-09 ES ES394914A patent/ES394914A1/es not_active Expired
- 1971-09-09 ES ES394918A patent/ES394918A1/es not_active Expired
- 1971-09-09 ES ES394915A patent/ES394915A1/es not_active Expired
- 1971-09-09 ES ES394913A patent/ES394913A1/es not_active Expired
- 1971-09-09 ES ES394917A patent/ES394917A1/es not_active Expired
- 1971-09-09 ES ES394919A patent/ES394919A1/es not_active Expired
-
1973
- 1973-06-06 JP JP48063730A patent/JPS5210863B1/ja active Pending
- 1973-06-06 JP JP48063729A patent/JPS5210862B1/ja active Pending
- 1973-06-06 JP JP48063727A patent/JPS5238556B1/ja active Pending
- 1973-06-06 JP JP48063728A patent/JPS5210861B1/ja active Pending
-
1975
- 1975-10-07 YU YU2545/75A patent/YU34662B/xx unknown
- 1975-10-07 YU YU2544/75A patent/YU34396B/xx unknown
- 1975-10-07 YU YU2546/75A patent/YU34663B/xx unknown
- 1975-10-07 YU YU2551/75A patent/YU34113B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL90029B1 (pl) | ||
| JPS5946216B2 (ja) | 4−フエニルピペリジン化合物の製法 | |
| JP2651043B2 (ja) | ジフェニルメチルピペラジン誘導体 | |
| DK160820B (da) | Analogifremgangsmaade til fremstilling af 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinolinderivater | |
| KR100315934B1 (ko) | 옥사-및티아-디아졸무스카린수용체길항제 | |
| CA2047307A1 (en) | Carbostyril derivatives | |
| JPH06509318A (ja) | トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物 | |
| US4778792A (en) | Use of 7-acyl benzoxazinones and their derivatives in treating atheromatous disorders | |
| SK158692A3 (en) | 2-amino-5-cyano-1,4-dihydropyridines, method of their preparation and their use in medicines | |
| SU990761A1 (ru) | Гидрохлориды производных 4-дифенилметилен-1-гидроксибензилпиперидина,обладающие свойством улучшать кровообращение | |
| US4678791A (en) | 6-phenyl-1,2-3,4,4a,5-6,10b-octahydrobenz(h)isoquinolines useful for treating depression | |
| PL84398B1 (en) | 1-(2'-cyano-phenoxy)-2-hydroxy-3-ethylamino-propane and salts thereof[us3732277a] | |
| FR2467203A1 (fr) | Derives de 1,2,4-oxadiazolin-5-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| CS214841B2 (en) | Method of making the tetrahydrochinolines | |
| PL84223B1 (pl) | ||
| JPH07101947A (ja) | フエニル−1,2,5−オキサジアゾール−カルボンアミド−2−オキシド | |
| WO1992001686A1 (en) | 1,4-disubstituted piperazines | |
| US5055490A (en) | Stereoisomers of benzonitrile derivatives, useful as cardiac arrhythmiac agents | |
| JPH0353314B2 (pl) | ||
| CA1211441A (fr) | Procede de preparation de nouvelles piperidinoguanidines substituees, et des compositions pharmaceutiques en renfermant | |
| PL90714B1 (pl) | ||
| HU221631B1 (hu) | Gyógyászatilag aktív 1,2,4-triazo [4,3-a]piridin enantiomerek és eljárás ezek, valamint piperazin-intermedierek előállítására | |
| DK149845B (da) | Analogifremgangsmaade til fremstilling af 2-((4-quinolinyl)-amino)-5-flourbenzoesyrederivater | |
| JPS5823675A (ja) | 新規ピリミジン化合物の製法 | |
| LU86198A1 (fr) | Nouveaux derives de la 1,4-dihydropyridine,leur preparation et leur utilisation comme medicaments |